| Region: | |
| Category: |
(20 reports matching your criteria)
|
Italy Pharmaceutical Market Overview – Challenging outlook due to austerity and falling birth rate
12/7/2012 | published by: Datamonitor
... payers seek to control healthcare spending, generic uptake will increase. Features and benefits Analysis of population demographics, economic indicators, and political developments in Italy. Insight into the healthcare system, drug regulation, drug pricing, drug reimbursement, ...
|
read more...
|
$5,700.00
|
|
EU Biosimilars Database
8/10/2012 | published by: Datamonitor
... Features and benefits Pipeline: details of the full pipeline of products, select all or filter by country and sort by a variety of criteria Product: select an individual product and view details of all associated ...
|
read more...
|
$15,200.00
|
|
Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth
7/10/2012 | published by: GBI Research
... “Biosimilars in Developed Countries - Launch of Biosimilar mAbs in Europe and New Regulatory Pathways in the US to Spur Market Growth” that provides key data, information and analysis of the major trends and issues ...
|
read more...
|
$3,500.00
|
|
Analysis of European Biosimilars Market
12/20/2011 | published by: Frost & Sullivan
... participants. This study is focused on established segments in Europe including Erythropoietin, Granulocyte Colony Stimulating Factors, Human Growth Hormones and emerging segments including monoclonal antibodies, Insulin and interferon. The established market segments consist of products ...
|
read more...
|
$6,500.00
|
|
The Pharmaceutical Market: Portugal
4/13/2011 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...
|
read more...
|
$1,040.00
|
|
Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
4/1/2011 | published by: GBI Research
... Pathways in the US and Europe - Development and Approval of Biosimilar mAbs May Face Tough Regulatory Environment” that provides key data, information and analysis of the major trends and issues affecting the global biosimilar ...
|
read more...
|
$3,500.00
|
|
Contract Manufacturing Organizations (CMO) in Eastern Europe - Inconsistent Demand and Competition from Asia Raises Concerns
10/15/2010 | published by: GBI Research
... Europe - Inconsistent Demand and Competition from Asia Raises Concerns” that provides key data, information and analysis of the major trends and issues affecting the Contract Manufacturing Organizations (CMO) in Eastern Europe. The report provides ...
|
read more...
|
$3,500.00
|
|
Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotechnology Clusters, Funding Characteristics and Regulatory Landscape
2/1/2010 | published by: GBI Research
... Enterprises in North America and Europe - Biotech Clusters, Funding Characteristics and Regulatory Landscape.” This pharmaceutical and healthcare report provides an overview of the small and medium biopharmaceutical enterprises in the North American and European ...
|
read more...
|
$3,500.00
|
|
H4-13, Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009
10/28/2009 | published by: Decision Resources
... governments in Japan and Germany, and new initiatives by governments in other countries to control their national pharmaceutical spending. Faced with declining revenues and increasing expenditures, healthcare payers in all markets are exerting increasing pressure ...
|
read more...
|
$4,600.00
|
|
The World Market for Biosimilars and the Potential for US Follow-on Biologics
8/1/2009 | published by: Kalorama Information
... areas in the world and the possibility of a U.S. Market in the near future. As part of its research, this Kalormaa Information report provides the following Current market size and forecasts for biogenerics in ...
|
read more...
|
$3,700.00
|
|
Biopharmaceutical Products In US And European Markets, 7th Ed ONLINE
6/1/2009 | published by: BioPlan Associates, Inc.
... in 2010, with reviews and analysis, including biogenerics Broader - Over 500 monographs with more European, biodefense and biogenerics coverage Better reference resource always up-to-date Bonus Sections - More reviews and analyses of products, FDA ...
|
read more...
|
$794.00
|
|
European Biosimilars Market Outlook
9/24/2008 | published by: Frost & Sullivan
... of the current situation in Europe, various issues surrounding biosimilars, key drivers, restraints and challenges facing market participants. In addition, it includes a segment-wise and country-wise market opportunity analysis followed by recommendations to market participants.
|
read more...
|
$6,500.00
|
|
Biosimilars: A Viable Market - But When?
9/9/2008 | published by: Espicom Healthcare Intelligence
... key issues such as development costs and legal matters Consideration of upcoming product opportunities Examination of the factors such as pricing and clinician response A review of the work of 42 companies actively developing biosimilar ...
|
read more...
|
$2,460.00
|
|
Access to Hospital Pharmaceutical Markets in the United Kingdom
8/1/2008 | published by: JustPharmaReports.com
... products also unable to get established for maintenance therapy in the community without hospital recommendation first. Though the processes for achieving hospital usage are very different to the reimbursed GP/community pharmacy sector, they have been ...
|
read more...
|
$1,350.00
|
|
Key Issues to Consider When Bringing Biologics to Market in Europe and Japan
7/28/2008 | published by: Decision Resources
... force in Europe and Japan, where they are well represented in companies' product pipelines. Issues that will make or break the successful integration of biologics in European and Japanese biopharmaceutical market include clinical trial design, ...
|
read more...
|
$1,125.00
|
|
A Guide to Biosimilars, Biogenerics and Follow-On Biologics
9/1/2007 | published by: Informa Healthcare
... opportunities presented by this market trend, as well as its challenges. With regulation playing a key role in the evolving landscape for biosimilar products, the report places particular emphasis on the regulatory situation in two ...
|
read more...
|
$2,300.00
|
|
European Fine Chemicals Markets - Investment Analysis and Growth Opportunities
7/26/2006 | published by: Frost & Sullivan
... & Sullivan biometrics stocks and valuation multiples for biometric companies. It includes a growth monitor that ranks companies based on prospective revenue growth, and industry growth outlook that discusses market estimates until 2008. In this ...
|
read more...
|
$6,000.00
|
|
R&D in Swedish Biopharma Companies 2002
9/25/2002 | published by: BioSeeker Group AB
... in 52 identified biopharma companies in Sweden. The predominant disease groups for R&D in Swedish biopharma are: Inflammation / autoimmune, metabolic, cancer, infectious, and neurological diseases, whilst treatments for dermatitis, psoriasis, asthma and osteoporosis are ...
|
read more...
|
$492.75
|
|
Swedish Biopharma Profiles 2002
9/25/2002 | published by: BioSeeker Group AB
... development (R&D) or search and development (S&D) in Sweden. We also present which major disease groups are targeted and the geographical distribution of biopharma companies in Sweden. Each profile contains contact details, financial information covering ...
|
read more...
|
$471.15
|
|
Swedish Biopharma Industry - The Next Wave
9/17/2002 | published by: BioSeeker Group AB
... Swedish Biopharma Industry-The Next Wave, BioSeeker Group analyzes in detail the pharmaceutical biotechnology (biopharma) industry segment in Sweden. In terms of numbers, biopharma is the second largest biotech industry segment in Sweden after the medical ...
|
read more...
|
$1,147.50
|